Southern Fund's Hong Kong Stock Connect Innovative Medicine ETF Southern (159297) surged more than 3.6% in early trading, with institutions remaining bullish on the long-term development logic of the innovative drug industry.

NightAirdropper · 2026-03-17T13:27:49+00:00

As of March 17, 2026, the Hong Kong Stock Connect Innovative Pharmaceutical ETF Southern (159297) demonstrated strong performance, rising more than 2.48%. Institutions believe that the core competitiveness of innovative pharmaceuticals has strengthened, and they are optimistic about long-term industry development, recommending attention to related targets and earnings recovery opportunities. The ETF closely tracks the innovative pharmaceutical index, providing a convenient investment tool.

NightAirdropper

2026-03-17 13:27:49

Abstract generation in progress

As of March 17, 2026, 11:11 AM, the Southbound Innovation Drug ETF (159297) of Hong Kong Stock Connect temporarily rose over 3.6%, up 2.48%, with a turnover rate of 6.55% during the trading session and a transaction volume of 107 million yuan. The tracking index, the China Securities Hong Kong Stock Connect Innovation Drug Index (987018), surged strongly by 2.29%.

Institutional research reports indicate that China’s core competitiveness in innovative drugs continues to strengthen. With recent annual report disclosures, the commercialization potential of some companies is expected to be realized. The long-term development logic of the innovative drug industry remains optimistic. It is recommended to focus on innovative drugs, Contract Research Organizations (CROs), and upstream segments of the life sciences industry, while also paying attention to themes such as brain-computer interfaces and AI applications. Due to international geopolitical influences, global oil prices have risen sharply, pushing up the prices of basic chemical raw materials, which has led to significant increases in raw drug prices such as vitamin A and vitamin E. It is advised to monitor the performance resilience of related companies. Additionally, as the annual report disclosure period begins, attention should be given to stocks showing signs of bottoming out.

The Southbound Innovation Drug ETF (159297) closely tracks the China Securities Hong Kong Stock Connect Innovation Drug Index, which aims to reflect the operational characteristics of listed companies in the innovative drug sector within the Hong Kong Stock Connect scope. The top ten holdings in the index are CSPC Pharmaceutical Group, Innovent Biologics, BeiGene, China Biological Products, Kangfang Biotech, Hansoh Pharmaceutical, Sihuan Pharmaceutical, Kelun-Biotech, Kintor Pharmaceutical, and United Laboratories.

As a convenient tool for investing in the Hong Kong stock innovation drug sector, the Southbound Innovation Drug ETF (159297) is currently in a “fundamentals improving, valuation relatively low, catalysts approaching” allocation window. The industry trend is clear, and its long-term investment value is highly regarded.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.